IVIG Sales

Discussion in 'Octapharma' started by Anonymous, Dec 27, 2013 at 9:48 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    In the big pic for blood product sales . . . . With the recent HRSA guidelines being enforced, the only way to make it in this business is to capture market share. Therefore the company that understands this, they will support 100% of customers 340B need, capture the market share, and increase price over time. Baxter figured it out b4 everyone else and it appears CSL is finely getting more aggressive with their offerings, ie - Fall Promo and Balanced Liter programs. This would not apply to Grifols, Kedrion, Octapharma, etc. as they do not have the volumes of plasma that Bax n CSL have.
    For large volume Sales, with Obama Care being implemented, Sales will be driven through the IDN level not via the hospital DOP or buyer. These products are too expensive to be driven at the hospital level.
    Also - those at the IDN level are tired of seeing four different reps from the same company. I think in short order the manufacturers will realize this and scale back on their field Sales force.
    As far as Octapharma goes - Does upper management have a clue as to what is going on in the US market? You need to hire some marketing professionals who have blood products experience and put together a "global plan"
    Food for thought.
     

  2. Anonymous

    Anonymous Guest

    Didn't you post this on the CSL site? It's not earth shattering enough to post on multiple sites.